Epix submits MR contrast agent for FDA approval

MRI pharmaceutical developer Epix Medical of Cambridge, MA, has submitted a new drug application (NDA) to the Food and Drug Administration for its MS-325 vascular contrast agent.

The agent is specifically designed for magnetic resonance angiography (MRA) and was co-developed by Epix and Schering of Berlin. The MS-325 NDA is the first application for marketing approval for an MR contrast agent to be submitted to the FDA for the primary indication of MRA, Epix said.

By AuntMinnie.com staff writers
December 16, 2003

Related Reading

Epix COO resigns, November 11, 2003

Epix continues to build revenues, trim losses in Q3, October 24, 2003

Epix to present phase III results, September 15, 2003

Epix exercises overallotment option, August 27, 2003

Epix sets share price, August 7, 2003

Copyright © 2003 AuntMinnie.com

Page 1 of 606
Next Page